Final call to support affordable CLL non-chemo treatment for Australians - and improve the chances of your country approving this very effective drug when the successes from Australian patients treated with Venetoclax are available for review by your government body assessing new CLL drugs.
All of us can submit comments, not just those in Australia, as has been proven by PaulaS, MsLockYourPosts and tekusa. Remember that the deadline is March 8th Australia time - that means you should submit your reply right now!
Venetoclax for relapsed/refractory CLL will be considered at this March's Pharmaceutical Benefits Advisory Committee (PBAC) meeting for consideration for inclusion on the Pharmaceutical Benefits Scheme. (PBS), hopefully making it the first affordable non-chemo treatment available for relapsed/refractory Australian CLL patients.
Patients, family members, health care organisations, clinicians, researchers and other stakeholders are welcome to provide feedback to PBAC via their online portal.
Please don’t underestimate the value of your feedback.
When asked for the meeting date - enter March 2017.
NOTE: The CLOSING date is this Wednesday 8th of February, 2017. That's NOW!
Thanks to Sharon Winton, CEO, Lymphoma Australia for bringing this to my attention.